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Mast cells reside on and near the cerebral vasculature, the predominant site of pneu-
mococcal entry into the central nervous system (CNS). Although mast cells have been 
reported to be crucial in protecting from systemic bacterial infections, their role in 
bacterial infections of the CNS remained elusive. Here, we assessed the role of mast 
cells in pneumococcal infection in vitro and in vivo. In introductory experiments using 
mouse bone marrow-derived mast cells (BMMC), we found that (i) BMMC degranu-
late and release selected cytokines upon exposure to Streptococcus pneumoniae, (ii) 
the response of BMMC varies between different pneumococcal serotypes and (iii) is 
dependent on pneumolysin. Intriguingly though, apart from a slight enhancement of 
cerebrospinal fluid (CSF) pleocytosis, neither two different mast cell-deficient Kit mutant 
mouse strains (WBB6F1-KitW/Wv and C57BL/6 KitW-sh/W-sh mice) nor pharmacologic mast 
cell stabilization with cromoglycate had any significant impact on the disease phenotype 
of experimental pneumococcal meningitis. The incomplete reversal of the enhanced CSF 
pleocytosis by local mast cell engraftment suggests that this phenomenon is caused by 
other c-Kit mutation-related mechanisms than mast cell deficiency. In conclusion, our 
study suggests that mast cells can be activated by S. pneumoniae in vitro. However, 
mast cells do not play a significant role as sentinels of pneumococcal CSF invasion and 
initiators of innate immunity in vivo.
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inTrODUcTiOn
Bacterial meningitis is among the top 10 causes of infection-related deaths worldwide, and many 
survivors suffer from permanent neurologic and otologic sequelae (1, 2). The most frequent causa-
tive agent in the Western world is Streptococcus pneumoniae (the pneumococcus), being responsible 
for more than half of all cases (1, 2). Pneumococcal infection of the meninges generates a strong 
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inflammatory reaction, which contributes substantially to brain 
damage in this disease (2). The immune response is initiated by 
the recognition of pathogen-associated molecular patterns on 
invading pathogens by host pattern recognition receptors (PRRs) 
like toll-like receptors (TLR). TLR engagement induces myeloid 
differentiation primary response gene (MyD) 88-dependent 
production of a vast array of pro-inflammatory host factors 
including cytokines, chemokines, and complement factors (2). 
As a consequence, large numbers of neutrophils are recruited 
into the cerebrospinal fluid (CSF)-filled leptomeningeal space. 
Rapid recruitment of neutrophils to sites of infection is required 
for an effective host defense against invading pathogens (3). 
However, their many defense mechanisms that destroy or digest 
pathogens can also be deleterious to host tissue. Over the past 
decades, evidence has accumulated that neutrophils are indeed 
major effectors of tissue damage in pneumococcal meningitis 
(4–6). Since they are virtually absent in normal CSF, other 
immunocompetent cells might function as sentinels of bacterial 
CSF invasion and initiators of the host immune response.
Among the potential candidates to act as sentinels are mast 
cells. They are typically found not only in the meninges and cho-
roid plexus but also within the brain parenchyma, particularly 
in the thalamic–hypothalamic region (7, 8). Mast cells generally 
reside on and near the vasculature, the predominant site of 
pneumococcal entry into the CSF (9). In vitro, mast cells, namely, 
the rat RBL-2H3 cell line, were found to respond by degranula-
tion upon exposure to S. pneumoniae (10). Moreover, human 
lung mast cells and the human mast cell lines HMC-1 and LAD 
exhibited direct antimicrobial activity against S. pneumoniae, 
presumably through a pneumolysin (PLY)-induced release of 
the antimicrobial peptide LL-37 (11). Surprisingly, in  vivo, in 
an experimental pneumococcal pneumonia model, mast cell-
deficient KitW-sh/W-sh mice showed reduced bacterial outgrowth, 
less inflammation, and prolonged survival as compared with 
wild-type (WT) mice (12). This finding contrasts with the 
until-recently widely held concept that mast cells are crucial in 
protecting the host from bacterial infections (13, 14). This per-
spective goes back to two seminal reports that demonstrated, by 
using mast cell-deficient KitW/Wv mice, that mast cells are crucial 
for the survival of mice subjected to cecal ligation and puncture 
(CLP)-induced sepsis or Klebsiella pneumoniae peritonitis 
(15, 16). The protective effect was linked to mast cell-mediated 
promotion of neutrophil recruitment to sites of infection 
through their release of pro-inflammatory mediators (17, 18). 
Subsequently, numerous reports were published corroborat-
ing this initial observation in various experimental infectious 
disease models including, for instance, Citrobacter rodentium-
induced colitis (19), experimental cystitis due to Escherichia coli 
infection (20), Staphylococcus aureus peptidoglycan-triggered 
diarrhea (21), Salmonella minnesota lipopolysaccharide-induced 
peritonitis (22), and Pseudomonas aeruginosa pneumonia (23), 
or encephalomyocarditis viral myocarditis (24). However, recent 
studies using two or more mast cell-deficient Kit mutant mouse 
strains and/or mutant mouse strains with unperturbed c-Kit 
function revealed a more complicated picture: depending on the 
nature of the mutation resulting in a mast cell deficiency as well 
as the type and severity of infection, mast cells can have no effect, 
aggravate, or attenuate inflammation and infectious disease 
severity (25–28). For example, mast cell engraftment enhances 
survival after moderately severe CLP in both WBB6F1-KitW/Wv 
mice and C57BL/6 KitW-sh/W-sh mice, but it either has no statisti-
cally significant effect on survival in WBB6F1-KitW/Wv mice or 
even impairs survival in C57BL/6-KitW-sh/W-sh mice (25). Thus, 
a conclusion for an absolute mast cell role in (infectious) diseases 
requires evidence from more than one mutant mouse strain 
(26, 29). Also of note, mast cell phenotype and function are direct 
consequences of the local microenvironment and have a marked 
influence on their ability to specifically recognize and respond to 
pathogens (30). Except for one study, which described a normal 
viral clearance, but less vigorous brain inflammation in mast 
cell-deficient mice as compared with WT mice when subjected 
to intracerebral Sindbis virus infection (31), investigations on 
the functional significance of mast cells in central nervous sys-
tem (CNS) (especially bacterial) infections were lacking.
To provide some insight into the role of mast cells in bacterial 
CNS infections, here we assessed the phenotype of two different 
mast cell-deficient Kit mutant mouse strains and also the treat-
ment effect of the so-called “mast cell stabilizer” cromoglycate 
in a well-established mouse model of pneumococcal meningitis 




All procedures were approved by the Committee on the Ethics 
of Animal Experiments of the Government of Upper Bavaria 
(Permit numbers 55.2-1-54-2531-67-99, -125-13) and carried 
out in accordance with the Principles of Laboratory Animal Care 
(European Commission Directive 2010/63/EU), the German 
Animal Welfare Act, and the ARRIVE guidelines (32). All experi-
ments were conducted on age-matched male, 10- to 16-week-old 
mice. All efforts were made to minimize animal suffering and the 
number of animals used (8–12 mice per group, based on power 
calculations at 80% power and significance level of 5%). C57BL/6 
mice (n = 30 in total), Kit mutant WBB6F1-KitW/Wv mice (n = 16, 
one mouse had to be euthanized due to neurologic abnormalities 
related to the meningitis induction procedure) and their congenic 
littermates WBB6F1-Kit+/+ (n =  12) and Kit mutant C57BL/6 
KitW-sh/W-sh mice (n = 25), and their WT controls C57BL/6 Kit+/+ 
(n =  11; one mouse developed clinical signs requiring eutha-
nasia) were purchased from Charles River Germany (Sulzfeld, 
Germany; the exclusive distributor of imported JAX® mice strains 
in Germany). KitW/Wv mice carry one allele (W) with a point 
mutation that produces a non-functional truncated receptor 
and another allele (W-v) that encodes a mutation in the kinase 
domain. They are profoundly mast cell deficient (33). KitW-sh/W-sh 
mice, in turn, have an inversion upstream of the Kit gene that 
leads to a selective reduction of Kit expression and hence severe 
mast cell deficiency (34, 35). Both mouse strains have white spot-
ted or all-white coats while their mast cell-sufficient congenic 
littermates have dark coat, preventing allocation concealment 
and blinding during assessment of clinical outcome. Before and 
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after meningitis induction, mice were housed in their home cages 
in a temperature-controlled environment, with a 12-h light dark 
cycle and were given access to food and water ad libitum.
induction of Pneumococcal Meningitis 
and clinical scoring
A well-characterized mouse model was used in this study (6, 36). 
Briefly, adult mice were weighed, and their body temperature was 
taken. Then, they were clinically examined and scored. Clinical 
scoring compromised (i) a beam balancing test, (ii) a postural 
reflex test, and (iii) monitoring of the presence of piloerection, 
seizures or reduced vigilance. The healthy mouse score was 
set to 0 points, while 13 points were attributed to terminally 
ill mice which were euthanized according to ethics guidelines. 
After clinical examination, bacterial meningitis was induced by 
intracisternal (i.c.) injection of 1 × 105 colony-forming units (cfu) 
S. pneumoniae serotype 2 (D39 strain) under short-term anesthe-
sia with isoflurane. Controls were i.c. injected with phosphate-
buffered saline (PBS). Eighteen hours later, mice were weighed, 
scored clinically, and temperature was measured again. After 
anesthesia with ketamine/xylazine, a catheter was placed into the 
cisterna magna. Through it, CSF was sampled for measurement 
of CSF interleukin (IL)-1β concentrations and white blood cell 
counts. Subsequently, blood samples were drawn by transcardial 
puncture. Deeply anesthetized mice were perfused with ice-cold 
heparin-containing PBS, and thereafter the brains (including cer-
ebella) were removed and further processed for microbiological 
and histological analyses.
Determination of Bacterial Titers  
in Blood and Brain
Cerebella were dissected and homogenized in sterile saline. 
Blood samples and cerebellar homogenates were diluted serially 
in sterile saline, plated on blood agar plates, and cultured for 24 h 
at 37°C with 5% CO2.
Brain cytokine expression Pattern
Mice brains were screened for 32 cytokines using a com-
mercially available cytokine antibody array (Mouse Cytokine 
Array C2 from RayBiotech Inc., USA). Detailed information 
about this array including antibody list, sensitivity data, and 
experimental protocol can be obtained at the supplier’s web-
site.1 Briefly, 30 µm thick brain sections were homogenized in 
lysis buffer (10  mM HEPES at pH 7.9, 10  mM KCl, 1.5  mM 
MgCl2, and a mixture of protease inhibitors, including phenyl-
methylsulfonyl fluoride, aprotinin, leupeptin, and pepstatin A), 
then centrifuged at 12,000 rpm for 15 min at 4°C. Protein con-
centrations were determined in supernatants using Nanoquant 
assay (Carl Roth GmbH, Karlsruhe, Germany), and equal pro-
tein amounts of 8 mice brains per group were pooled. A total 
of 1,500  µg pooled protein was applied per array membrane 
and handled according to the manufacturer’s instructions. 
For evaluation, membranes were digitized and analyzed as 
described previously (37).
1 www.raybiotech.com.
Measurement of Brain il-1β
Mouse brain IL-1β concentrations were determined by ELISA 
according to the manufacturer’s instructions (R&D Systems, 
Wiesbaden-Nordenstadt, Germany).
gene array analysis
The relative mRNA expression of cytokines, chemokines, and 
some related inflammatory genes was analyzed with a pathway-
specific oligonucleotide microarray. The mouse inflammatory 
cytokines and receptor Oligo GEArray® (OMM-011; Superarray 
Inc., Bethesda, MD, USA) contain 112 inflammatory cytokines 
and receptors genes, and different housekeeping genes. Detailed 
information about this oligonucleotide array including descrip-
tion of gene probes, experimental protocol, and data analysis 
method can be obtained at the supplier’s website.2 In brief, 
3  µg of total RNA that was extracted from frozen brain sec-
tions with TRIzol® reagent (Invitrogen) and pooled from brain 
extracts of eight mice per group was reverse transcribed. Then, 
biotin-labeled cRNA was synthesized from cDNA with the use 
of the TrueLabeling-AMP™ Linear RNA Amplification Kit 
(Superarray). cRNA was purified using the ArrayGrade cRNA 
Cleanup Kit (Superarray), quantified, and hybridized overnight 
to inflammatory cytokine and receptor gene-specific probes that 
were spotted on the GEArray membranes. After incubation with 
streptavidin–AP conjugate, the array image was developed with 
CPD-Star chemiluminescent substrate (Superarray), recorded 
with X-ray film, scanned into raw data and analyzed by TINA 
2.08e software (Raytest) (37). To test the validity of the method, 
the brain mRNA expression of cytokines, namely, Il-1β, IL-33, 
and IL-6, were also examined by RT-PCR according to the meth-
ods described previously (38).
experimental groups
To characterize the role of mast cells in the pathobiology of 
pneumococcal meningitis, we compared the disease phenotypes 
of two different mast cell-deficient c-Kit mutant mouse strains, 
namely, WBB6F1-KitW/Wv mice (n = 12) and C57BL/6 KitW-sh/W-sh 
mice (n = 8) with that of their respective control strains (n = 12 
and n =  10, respectively). For mast cell engraftment studies, 
4-week-old C57BL/6 KitW-sh/W-sh mice (n = 6) were reconstituted 
i.c. with 106 bone marrow-derived mast cells (BMMC; for prepa-
ration, see below) in 50 µl PBS through transcutaneous injection 
under short-term isoflurane anesthesia. Reconstitution was 
confirmed by toluidine blue staining of brain sections. In addi-
tional experiments, we evaluated the effect of the pharmacologic 
mast cell stabilizer cromoglycate (n  =  10) in C57BL/6 mice 
with pneumococcal meningitis. Controls (10 C57BL/6 mice, 
3 WBB6F1-KitW/Wv mice, and C57BL/6 KitW-sh/W-sh mice each) 
received the vehicle (PBS) alone. Cromoglycate was given i.c. 
(at a dosage of 75 µg/mouse) because it only minimally crosses 
the BBB (39, 40).
Toluidine Blue staining of Brain section
For determination of mast cell numbers in control and infected 
brains, brain hemispheres were fixed in 10% formalin and 
2 www.superarray.com.
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embedded in paraffin. Brains were cut coronally into 5 µm thick 
sections using a microtome and stained with acidic toluidine 
blue, according to standard protocols (41). The numbers of brain 
mast cells were determined microscopically at 200× magnifica-
tion in 10 systematically selected brain sections containing lateral 
ventricles and the dentate gyrus and given as n per square meter. 
All counts were carried out on coded slides by a single observer.
cell culture experiments
Mouse mast cells (BMMC) were prepared from bone marrow 
cells isolated from femora, as described by Jensen et al. (42) with 
slight modifications. Briefly, femora were flushed with Hanks’ 
balanced salt solution, and the cell suspension was forced through 
a 70-µm mesh. Collected cells were resuspended in complete 
mast cell medium containing RPMI1640, 10% heat-inactivated 
fetal bovine serum (FBS), 2 mM glutamine, 1 mM sodium pyru-
vate, 50 µM 2-mercaptoethanol, 100 U/ml penicillin, 100 µg/ml 
streptomycin, 10 ng/ml recombinant murine IL-3, and 10 ng/ml 
recombinant murine stem cell factor (SCF; both from Peprotech, 
Hamburg, Germany), and cultured at 37°C in 5% CO2. Cells were 
transferred periodically to fresh flasks to remove adherent cells, 
and maintained for 4–6 weeks to allow mast cell differentiation. 
At this time, more than 96% of cells expressed the mast cell mark-
ers c-Kit (CD117) and Fc-epsilon receptor I, as determined by 
flow cytometry analysis.
Mast cell Degranulation assay
Bone marrow-derived mast cells were washed thrice with PBS, 
re-suspended in HEPES buffer (pH 7.4, 10 mM HEPES, 137 mM 
NaCl, 2.7 mM KCl, 0.4 mM Na2HPO4, 5.6 mM glucose, 1.8 mM 
CaCl2, 1.3 mM MgSO4, and 0.04% bovine serum albumin) and 
seeded in a 96-well microtiter plate at a density of 105 cells/100 μl, 
followed by stimulation with (penicillin–streptomycin-lysed) 
S. pneumoniae or its vehicle solution (Todd’s Hewitt broth plus 
0.5% yeast extract, THY) for 30 min at 37°C. The stimulation 
protocols included (i) different concentrations of S. pneumoniae 
serotype 2, (ii) additional S. pneumoniae serotypes, namely, 
a PLY-deficient isogenic D39 mutant (D39Δply) as well as a 
serotype 3, 7F, and 19A, (iii) different concentrations of recom-
binant PLY [expressed and purified as described previously 
(43)], (iv) selected sets of pharmacologic inhibitors, including 
anti-TLR2- and anti-TLR4-neutralizing antibodies [clones 
T2.5 and 1A6, from Hycult Biotech, Germany, and NovImmun 
SA, Switzerland, respectively, each at a dosage of 25  µg/ml 
(44)], the endosomal TLR antagonist chloroquine (20  µg/ml, 
Sigma-Aldrich GmbH, Germany) (45), and cromoglycate (0.1, 1, 
and 10  mM, Sigma-Aldrich GmbH), and (v) BMMC derived 
from mouse strains with genetic deficiencies in the TLR 
signaling pathway, namely, MyD88/TRIF−/− mice (resulting in 
a complete loss of TLR signaling), 3d/Tlr2/4−/− (lacking TLR2 
and TLR4 expression besides carrying a neutralizing missense 
mutation in UNC93b1 named 3d, leading to abrogation of 
TLR3, TLR7, TLR9, TLR11, TLR12, and TLR13 function), and 
TLR2/3/4/7/9−/− mice, as well as BMMC derived from mice lack-
ing apoptosis-associated speck-like protein (ASC−/−) and thus 
S. pneumoniae-induced caspase-1 activation and IL-1β/IL-18 
secretion (46, 47) (femora from all these mouse strains were 
kindly provided by Prof. Carsten Kirschning, University of 
Duisburg-Essen, Germany). The calcium ionophore A23187 
(1 µM; Sigma-Aldrich) was used as a positive control (PC). At the 
end of the stimulation period, microtiter plates were centrifuged, 
supernatants were collected, and cell pellets were solubilized 
in HEPES buffer supplemented with 0.1% Triton-X. Then, the 
β-hexosaminidase activity in cell lysates and supernatants were 
determined as previously described by Kuehn et  al. (48). The 
percentage of β-hexosaminidase release, indicating the extent of 
degranulation, was calculated as the ratio of absorbance of the 
supernatant to the sum of absorbance in the supernatant and cell 
lysate, multiplied with 100.
Mast cell stimulation and Measurement  
of cytokine release
Bone marrow-derived mast cells were washed thrice with PBS, 
resuspended in serum-, IL-3- and SCF-free mast cell medium 
(containing nutridoma-SP instead of FBS), and seeded in a 
96-well microtiter plate at a density of 2 × 105 cells/200 μl. After 
1 h of rest, BMMC were stimulated with S. pneumoniae accord-
ing to the protocol of the degranulation experiments. Six hours 
post pneumococcal challenge supernatants were harvested and 
assayed for cytokines. Controls received THY instead of S. pneu­
moniae. For screening purposes, supernatants from control and 
S. pneumoniae-challenged cells were subjected to a mouse Multi-
Analyte ELISA Array Kit (M-005a; Qiagen, Hilden, Germany). 
In all other experiments, supernatants were assessed for the pres-
ence of mouse IL-6 and CCL2 using mouse DuoSet ELISA Kits 
(R&D Systems, Bio-Techne, Wiesbaden, Germany). Moreover, 
the LDH activity, a marker of cell damage, was determined in 
supernatants (S), centrifuged supernatants of control cells after 
lysis with Triton X-100 (PC), and in control medium [negative 
control (NC)] using a colorimetric assay kit (BioVision, Biocat 
GmbH, Heidelberg, Germany). Cytotoxicity was calculated as 
percentage LDH release by the ratio of (S − NC/PC − NC) − 100.
statistical analysis
The principal statistical test was one-way analysis of variance 
and subsequent Bonferroni post hoc tests. Differences were con-
sidered significant at P < 0.05. Data are displayed as means ± SD.
resUlTs
S. pneumoniae induces Degranulation  
and selected cytokine Production  
of Murine BMMc In Vitro
Data on the impact of S. pneumoniae on cultured mast cells are 
scarce and inconsistent: live (but not heat-killed) S. pneumoniae 
(serotype 2; D39 strain) triggered mast cell degranulation with-
out concomitant cytokine (TNF-α and of IL-6) release in a rat 
mast cell line (10), whereas exposure of human lung mast cells 
and mast cell lines to the identical pneumococcal strain led to 
leukotriene C4 and antimicrobial peptide LL-37 release without 
histamine [a degranulation marker (49)] and cytokine liberation. 
To get a first hint into the responsiveness of murine BMMC to 
pneumococcal challenge, we stimulated 4- and 6-week-old mast 
FigUre 1 | Mouse bone marrow-derived mast cells (BMMC) are activated upon exposure to Streptococcus pneumoniae in vitro. To get first insight into the role of 
mast cells in S. pneumoniae infection, we analyzed responsiveness of mouse BMMC toward pneumococcal challenge using different S. pneumoniae concentrations 
(a–D), serotypes (e–h), and different recombinant pneumolysin (PLY) concentrations (i–M). Supernatants were collected 6 h after challenge, and interleukin (IL)-6 
(a,e), CCL2 (B,F), β-hexosaminadase (c,g), and LDH (D,h) contents were analyzed by standard assays. For β-hexosaminadase release measurements, the 
calcium ionophore A23187 served as positive control (PC). For LDH determinations, BMMC lysed by Triton X-100 were used as PCs. Controls received THY  
instead of S. pneumoniae. Abbreviations: ST, serotype; cfu, colony forming units. All experiments were—at least—carried out thrice in duplicates. Data are given  
as means ± SD. *P < 0.05, compared with 5 × 106 cfu/ml S. pneumoniae ST2; #P < 0.05, compared with 107 cfu/ml S. pneumoniae ST2; §P < 0.05, compared  
with 107 cfu/ml S. pneumoniae ST2; $P < 0.05, compared with 107 cfu/ml S. pneumoniae ST19A; +P < 0.05, compared with 500 ng/ml PLY, and &P < 0.05, 
compared with 250 ng/ml PLY, using ANOVA and Student–Newman–Keuls test for post hoc analysis.
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cells with antibiotic-lysed S. pneumoniae (serotype 2; D39) and 
analyzed supernatants for the presence of 12 different cytokines 
using a Multi-Analyte ELISA Array Kit. Six hours post chal-
lenge, substantially elevated levels of IL-6, CCL2, CCL3, and 
CCL4 (but not IL-1β, TNF-α, IFN-γ, IL-12. IL-17A, IL-4, IL-10, 
and TGF-β1) were detectable in supernatants from stimulated 
BMMC as compared with control cells (irrespective of the 
mast cell culture duration; data not shown). Next, we investi-
gated the concentration and serotype dependence of mast cell 
activation upon S. pneumoniae stimulation. The production of 
cytokines (we selected two out of the four alternatives presented 
by the Multi-Analyte ELISA investigations, namely, IL-6 and 
CCL2) was significantly increased at D39 infectious doses of 
5 ×  106 and 1 ×  107 cfu/ml, but neither at lower nor at higher 
bacterial concentrations (Figures  1A,B). Quite similar results 
were obtained with the β-hexosaminidase degranulation assay 
(Figure  1C). The decline in cytokine and β-hexosaminidase 
release observed at higher bacterial concentrations is probably 
due to a substantial cytotoxicity of S. pneumoniae (serotype 2) 
on BMMC, as indicated by the detection of high LDH in the 
supernatant (Figure 1D). Furthermore, cytokine production and 
degranulation varied substantially between mast cells stimulated 
with different pneumococcal serotypes (Figures 1E–H): IL-6 and 
CCL2 production was observed only after exposure of mast cells 
to serotype 2 and 19A, but not to serotype 3 and 7F pneumococci. 
Mast cell degranulation occurred solely after challenge with the 
serotype 2 strain. Of note, genetic depletion of PLY resulted in a 
complete loss of the mast cell activating potency of the serotype 
2 strain D39Δply (Figures 1E–H) and recombinant PLY on its 
own was able to induce cytokine production and degranulation 
of BMMC (Figures 1I–M). All in all, our data propose that mouse 
BMMC respond to S. pneumoniae infection with the release of 
selected host factors, and the BMMC response varies between 
serotypes and is largely dependent on the presence of PLY.
Mast cell activation by S. pneumoniae 
Does not involve Tlr signaling
Recent investigations in cultured macrophages suggest 
involvement of TLR2, TLR4, and TLR9 in pneumococcal 
sensing in  vitro (2). These TLRs have also been identified 
on and/or in murine BMMC (50). To assess their role in 
S. pneumoniae–BMMC interaction, we first stimulated BMMC 
with serotype 2 pneumococci in the absence or presence of 
FigUre 2 | Bone marrow-derived mast cells (BMMC) activation in response to Streptococcus pneumoniae challenge occurs independently of toll-like receptors 
(TLR) signaling. To evaluate the role of TLR in S. pneumoniae–BMMC interaction, we assessed the responsiveness of BMMC to pneumococcal challenge  
(107 cfu/ml) in the absence or presence of different TLR antagonists (including blocking antibodies directed against TLR2 or TLR4 and the endosomal TLR 
antagonist chloroquine). BMMC from mice with deficiencies in TLR signaling (including MyD88/TRIF-, TLR2/3/4/5/7/9-, and 3d&TLR2/4-deficent mice) or in the 
inflammasome component ASC were used in additional experiments. Supernatants were collected 6 h after challenge, and interleukin (IL)-6 (a,D), CCL2 (B,e), and 
β-hexosaminadase (c,F) levels were analyzed by standard assays. To determine the differentiation state of BMMC, cells sampled 6 weeks after the start of culture 
were subjected to immunophenotyping by flow cytometry using FcεRI and CD117 antibodies (g). All experiments were—at least—carried out twice in triplicates. 
Data are given as means ± SD. *P < 0.05, compared with untreated, stimulated BMMC; #P < 0.05, compared with vehicle (combination of isotype antibodies plus 
sterile deionized water, the vehicle of chloroquine)-treated, stimulated BMMC; and §P < 0.05, compared with stimulated wild-type BMMC, using ANOVA and 
Student–Newman–Keuls test for post hoc analysis.
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different TLR antagonists. Supplementation of the cell culture 
medium with the endosomal TLR antagonist chloroquine, 
but not with neutralizing antibodies directed against TLR2 or 
TLR4, resulted in a significant inhibition of S. pneumoniae– 
induced IL-6 and CCL2 production, but had no effect on 
β-hexosaminidase release (Figures  2A–C). The combined 
addition of chloroquine and anti-TLR2/4 antibodies showed 
no further effect on S. pneumoniae-triggered cytokine release. 
Since chloroquine is known to exert other immunomodulatory 
effects than inhibition of endosomal TLR signaling (51, 52), 
we conducted additional experiments using BMMC from mice 
with profound deficiencies in TLR signaling. Upon exposure 
to S. pneumoniae, MyD88/TRIF−/− BMMC released signific an-
tly lower amounts of IL-6 and CCL2 (but not β-hexosaminidase) 
into the cell culture supernatant as compared with WT BMMC 
(Figures 2D–F). Surprisingly, BMMC obtained from 3d/Tlr2/ 
4−/− mice lacking TLR2 and TLR4 expression besides carrying a 
neutralizing missense mutation in UNC93b1 named 3d (lead-
ing to abrogation of TLR3, TLR7, TLR9, TLR11, TLR12, and 
TLR13 function), and from TLR2/3/4/7/9−/− mice exhibited 
no difference to WT BMMC in respect to both, cytokine and 
β-hexosaminidase release, arguing against an involvement of 
TLR in S. pneumoniae–induced BMMC activation. Of note, 
flow cytometric immunophenotyping analysis revealed an 
impaired differentiation of MyD88/TRIF−/− bone marrow cells 
into mast cells, as compared with WT, but also 3d/Tlr2/4−/− and 
TLR2/3/4/7/9−/− cells: for instance, after 6 weeks of culture, only 
75% of MyD88/TRIF−/− BMMC expressed the mast cell mark-
ers c-Kit and Fc-epsilon receptor I, whereas 99, 91, and 91% 
of WT, 3d/Tlr2/4−/−, and TLR2/3/4/7/9−/− cells were c-Kit—and 
Fc-epsilon receptor I—positive, respectively (Figure  2G). 
As a consequence, the number of BMMC was substantially 
lower in the MyD88/TRIF−/− group as compared with all other 
experimental groups, possibly explaining the reduction in IL-6 
and CCL2 levels in the supernatants from MyD88/TRIF−/− 
BMMC cultures. Since MyD88 also acts as an adapter in the 
signaling cascade of IL-1 family cytokines, we additionally 
assessed the phenotype of ASC−/− BMMC following exposure 
FigUre 3 | Central nervous system mast cell numbers are reduced during 
murine pneumococcal meningitis. The images show representative toluidine 
blue-stained brain sections from control mice (a,c) and mice subjected to 
pneumococcal meningitis (B,D). Images (a,B) show cutouts of the 
leptomeningeal space, whereas (c,D) show cutouts of the ventricles. Mast 
cells stain purple with toluidine blue; arrows indicate representative mast 
cells. The number of toluidine blue-positive cells was determined in 10 brain 
sections containing lateral ventricles and the dentate gyrus (thereby focusing 
on the leptomeningeal space and ventricles) and given as n per brain section 
(e). Scale bars: 100 µm. Data are given as means ± SD. *P < 0.05, 
compared with the number of mast cells within the ventricles in control mice; 
#P < 0.05, compared with the total number of mast cells in control mice, 
using Mann–Whitney rank sum test.
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to S. pneumoniae. ASC is a critical factor for inflammasome 
formation and subsequent caspase-1 activation and IL-1 family 
cytokine secretion (47, 53, 54). The differentiation behavior of 
ASC−/− BMMC was equal to that of WT cells: 97% of ASC−/− cells 
expressed the mast cell markers c-Kit and Fc-epsilon receptor 
I after 6 weeks of culture. Moreover, ASC−/− BMMC exhibited 
no difference to WT BMMC in respect to both, cytokine and 
β-hexosaminidase release. Thus, (autocrine) IL-1 signaling is 
unlikely to contribute to the phenotype of MyD88/TRIF−/− 
BMMC (Figures 2D–F).
The number of Metachromatically  
stained Mast cells is reduced in the  
Brain During Pneumococcal Meningitis
To investigate whether the CNS mast cell population is affected 
by pneumococcal meningitis, we counted the number of 
metachromatically stained mast cells within the leptomeningeal 
space and lateral ventricles in brain sections obtained from 
control and infected mice. Compared with control mice, mice 
subjected to pneumococcal meningitis showed lower numbers of 
metachromatic cells within the CNS (especially within the lateral 
ventricles) at 18 h post infection, suggesting the occurrence of 
mast cell degranulation and/or death during pneumococcal 
meningitis (Figure 3).
WBB6F1-KitW/Wv Mice are Fully 
susceptible to Pneumococcal Meningitis
The vast majority of the existing data on the role of mast cells in 
(infectious) diseases is based on experiments in WBB6F1-KitW/Wv 
mice (26). WBB6F1-KitW/Wv mice were used in the only study 
so far assessing the role of mast cells in an experimental model 
of brain infection (with Sindbis virus) (31), and exhibited an 
attenuated immune response and impaired viral clearance. In our 
murine pneumococcal meningitis model, however, WBB6F1-
KitW/Wv developed disease comparable to their WT littermates 
WBB6F1-Kit+/+: The clinical scores, body temperatures, and 
the meningitis-associated losses in body weight did not differ 
significantly between both mouse strains (Figures 4A–C). Since 
mast cells (from human lungs) were reported to exhibit direct 
antimicrobial activity to S. pneumoniae (11), we also determined 
bacterial loads in brain and blood samples 18  h post infec-
tion, by plating of the samples and quantification of cfu. The 
analysis revealed no significant differences in the amounts of 
S. pneumoniae when comparing mast cell-sufficient and - 
deficient mice (Figures  4D,E). However, significantly higher 
leukocyte numbers were found in the CSF of infected WBB6F1-
KitW/Wv mice as compared with WT littermates (Figure  4F). 
This finding prompted us to analyze the expression of cytokines 
associated with host inflammatory responses. To get an exhaus-
tive survey, inflammatory cytokine and receptor expression 
was determined in RNA isolated from frozen brain sections 
of control mice, infected WBB6F1-Kit+/+ and WBB6F1-KitW/Wv  
mice. The expression of over 20 cytokines, chemokines, and 
related inflammatory factors was more than twofold upregu-
lated or induced in brains from infected, mast cell-sufficient 
mice, including IL-1β, IL-6, TNF-α, CXCL2, CXCL10, CCL3, 
and CCL4 (for more detailed information see Figures S1A,B 
in Supplementary Material). The expression level of all these 
factors did not differ substantially between brains from infected 
mast cell-sufficient and mast cell-deficient mice. In line with 
these findings, quantitative RT-PCR analysis of IL-1β and IL-33 
mRNA brain expression showed similar levels in both mouse 
strains (Figures S1C,D in Supplementary Material). The find-
ing that brain inflammation was equal in WBB6F1-Kit+/+ and 
WBB6F1-KitW/Wv mice was further strengthened by cytokine 
antibody array analysis. Compared with the cytokine protein 
expression in control brains, 7 out of 32 cytokines were induced 
or upregulated in brains of infected WBB6F1-Kit+/+ mice. 
Among them were the cytokines IL-6, IL-12, and G-CSF and the 
chemokines CXCL1, CXCL2, CCL2, and CCL5 (Figures 4E–G). 
There were no differences in the expression levels of all these 
factors between infected WBB6F1-Kit+/+ and WBB6F1-KitW/Wv 
mice. Moreover, ELISA measurements on CSF samples revealed 
similar increases in IL-1β concentrations in both groups as 
compared with control mice (Figure  4H). All in all, except 
for a more pronounced CSF pleocytosis, mast cell-deficient 
WBB6F1-KitW/Wv mice showed a similar disease phenotype as 
their mast cell-sufficient littermates.
neither Mast cell Deficiency due to the 
KitW-sh/KitW-sh Mutation nor Pharmacologic 
Mast cell stabilization influences the 
Disease Phenotype
In addition to their mast cell defects, KitW/Wv mice have multiple 
hematopoietic abnormalities including compromised fitness 
of hematopoietic stem and progenitor cells, and macrocytic 
anemia (26). Importantly, they are neutropenic which may be a 
major factor affecting immune responses in this strain (26, 55). 
FigUre 4 | WBB6F1-KitW/Wv mice are fully susceptible to pneumococcal meningitis. Pneumococcal meningitis was induced by intracisternal injection of 
Streptococcus pneumoniae. Eighteen hours later, animals were evaluated. Except of increased cerebrospinal fluid (CSF) white blood cell (WBC) counts  
(F), WBB6F1-KitW/Wv mice showed a similar disease phenotype as WBB6F1-Kit+/+ mice, as evidenced by similar clinical score values (a), body temperatures  
(B), weight losses (c), and brain and blood bacterial titers (D,e). The increase in CSF WBC counts was not associated with increased expression of inflammatory 
mediators within the central nervous system, as shown by protein array analyses on brain homogenates (g) and interleukin (IL)-1β ELISA on CSF samples  
(h). Data are given as means ± SD. *P < 0.05, compared with infected WBB6F1-Kit+/+ mice; #P < 0.05, compared with infected WBB6F1-KitW/Wv mice,  
using ANOVA and Student–Newman–Keuls post hoc test.
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Owing to these limitations, we additionally evaluated the 
disease phenotype in another mast cell-deficient, Kit mutant 
mouse strain (C57BL/6 KitW-sh/W-sh mice) as well as in WT mice 
following treatment with the mast cell stabilizer cromoglycate. 
The disease phenotype of C57BL/6 KitW-sh/W-sh mice matched 
that of WBB6F1-KitW/Wv mice: the clinical status, the body 
temperature, the loss of body weight, as well as the bacterial 
concentrations in the brain and blood (not shown) did not dif-
fer from that of infected C57BL/6 Kit+/+ mice (Figures 5A–D). 
Also similar to WBB6F1-KitW/Wv mice, infected KitW-sh/W-sh mice 
exhibited significantly higher CSF leukocyte numbers than the 
respective controls whereas CSF IL-β levels were quite similar 
between both mouse strains (Figures 5E,F). To evaluate whether 
the more pronounced CSF pleocytosis could be reversed by 
selective repair of the mast cell deficiency, mast cell-deficient 
KitW-sh/W-sh mice were engrafted i.c. with BMMC from C57BL/6 
Kit+/+ mice. The success of mast cell engraftment was assessed 
by toluidine blue histological staining of brain sections obtained 
from infected Kit+/+, KitW-sh/W-sh, and engrafted KitW-sh/W-sh mice: 
meningeal mast cell numbers were comparable between Kit+/+ 
and engrafted KitW-sh/W-sh mice (3.7 ± 1.5 and 3.1 ± 1.9 cells/brain 
section, respectively), whereas ventricular mast cell numbers 
tended to be lower in engrafted KitW-sh/W-sh mice than in Kit+/+ 
mice (2.0 ± 1.5 and 1.2 ± 1.1 cells/brain section, respectively). 
No mast cells were detectable in brain sections from KitW-sh/W-sh 
mice. Although quite successful, mast cell engraftment resulted 
only in a partial reversal of CSF leukocyte counts to WT levels 
(of note, leukocyte counts were determined in CSF samples 
obtained by puncture of the cisterna magna, that is, the menin-
geal compartment), suggesting that mast cell-independent 
effects of the Kit mutation contribute to this phenomenon. 
Therefore, as a Kit mutation-independent approach, we exam-
ined the effect of the well-known mast cell stabilizer cromo-
glycate in our meningitis model (40, 56, 57). In vitro, we found 
that cromoglycate (when given in a concentration of 10 mM) 
was capable of blocking cytokine production and degranulation 
FigUre 5 | C57BL/6 KitW-sh/W-sh mice show a similar disease phenotype of pneumococcal meningitis than their respective wild-type (WT) littermates. Pneumococcal 
meningitis was induced by intracisternal injection of Streptococcus pneumoniae. Eighteen hours later, animals were evaluated. Except of increased cerebrospinal 
fluid (CSF) white blood cell (WBC) counts, C57BL/6 KitW-sh/W-sh mice showed a similar disease phenotype as their WT controls C57BL/6 Kit+/+ mice, as evidenced by 
similar clinical score values (a), body temperatures (B), weight losses (c), and brain bacterial titers (D). The increase in CSF WBC counts (e) was not associated 
with increased CSF concentrations of interleukin (IL)-1β, as shown by ELISA analysis (F). When injected intracisternally with phosphate-buffered saline, C57BL/6 
KitW-sh/W-sh mice had CSF WBC numbers (0.33 ± 0.28 × 103 cells/μl) equal to that of C57BL/6 Kit+/+ mice. Data are given as means ± SD. *P < 0.05, compared  
with infected C57BL/6 Kit+/+ mice; #P < 0.05, compared with infected C57BL/6 KitW-sh/W-sh mice, using ANOVA and Student–Newman–Keuls post hoc test.
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of murine BMMC upon exposure with S. pneumoniae (Figures 
S2A–D in Supplementary Material). In vivo, cromoglycate was 
given directly into the CSF to guarantee that the drug reaches 
the targeted cells. Treatment with cromoglycate was ineffective 
in modulating the disease phenotype in the mouse meningitis 
model: cromoglycate-treated mice had similar clinical score 
values (6.2 ±  3.1 in cromoglycate-treated mice and 5.9 ±  3.5 
in vehicle-treated mice), brain bacterial titers (6.3 ±  0.5 and 
6.4 ± 0.7 log cfu/organ, respectively), as well as CSF leukocyte 
counts (16,271 ± 4,407 and 14,138 ± 4,529 cells/μl, respectively) 
as vehicle-treated control mice. All in all, our data suggest that 
mast cells are dispensable for the combat of S. pneumoniae 
infection inside the CSF.
DiscUssiOn
Mast cells are present in the meninges and choroid plexus, where 
they reside in the vicinity of small vessels. They are, therefore, 
ideally placed to participate in early pathogen recognition. 
In vitro, rat and human mast cells respond to infection with 
serotype 2 S. pneumoniae by releasing selected immune factors 
(10, 58). Here, we extend this finding and show that (i) mouse 
BMMC degranulate and release IL-6, CCL2, CCL3, and CCL4 
(but not, for instance, IL-1β and TNF-α) upon exposure to the 
same infectious agent, (ii) the response of BMMC varies between 
different pneumococcal serotypes and (iii) is dependent on PLY, 
but independent on TLR activation. Based on these findings, we 
anticipated that the absence of mast cells or pharmacologic mast 
cell stabilization (by cromoglycate) may reduce inflammation and 
ameliorate disease severity following intracisternal infection of 
mice with S. pneumoniae. Intriguingly though, apart from a slight 
enhancement of CSF pleocytosis, we did neither observe any 
effects of mast cell deficiency on brain cytokine and chemokine 
expression nor on disease severity. In addition, neither mast 
cell deficiency nor cromoglycate treatment had any impact on 
pneumococcal growth and dissemination in pneumococcal 
meningitis.
There is now a wealth of evidence suggesting that mast cells 
are crucial players in the host defense toward bacterial insults. 
Mast cells can modulate host innate immunity by releasing 
preformed and/or newly synthetized mediators (13). Their 
release is triggered through recognition of bacteria or bacterial 
products by various PRRs expressed on the cell surface or within 
endocytic vehicles (14) and, depending on the activating signal, 
exhibits distinct dynamics and features that are associated 
with distinct inflammation patterns (14, 59). Accordingly, we 
detected substantial differences in the BMMC reaction to differ-
ent pneumococcal serotypes: while challenge with a serotype 2 
strain caused both, mast cell degranulation and cytokine release, 
stimulation with a serotype 19A strain only triggered cytokine 
secretion, and exposure to serotype 3 or 7F strains was even inef-
fective. A possible explanation for this finding may be that the 
serotypes differ in their expression of the cholesterol-dependent 
cytolysin PLY, as demonstrated by Western immunoblotting 
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and a standard hemolysis test (Figures S3A,B in Supplementary 
Material). PLY seems to be important for mast cell activation 
upon S. pneumoniae infection as it can stimulate human lung 
mast cells to release the antimicrobial peptide LL-37 and the 
pro-inflammatory mediator LTC4 (11). Accordingly, we found 
that, in the serotype 2 strain, genetic deletion of PLY results in 
complete loss of its ability to activate BMMC. The mechanism 
through which PLY activates mast cells is not known. Based 
on previous reports that PLY can activate TLR4 (60) and that 
mast cells can express most of the common TLR including 
TLR1–9 (14), TLR involvement has been speculated (11). 
By using pharmacologic TLR antagonists and BMMC from 
TLR-deficient mice, however, we were unable to find evidence 
for a linkage between TLR and S. pneumoniae-induced BMMC. 
Of note, these experiments were hampered by possible pharma-
cologic side effects of chloroquine (51, 52) and by an incomplete 
differentiation of MyD88/TRIF−/− bone marrow into mast cells, 
as evidenced by FACS immunophenotyping for the mast cell 
marker c-Kit and Fc-epsilon receptor I. Also of note, our 
observation that BMMC can release selected cytokines (namely, 
IL-6, CCL2, CCL3, and CCL4) in response to pneumococcal 
challenge is in contradiction to previous studies: Barbuti et al. 
(10) failed to show IL-6 and TNF-α production in the rat mast 
cell line RBL-2H3, and Cruse et al. (11) did not detect synthesis 
of several cytokines (including IL-6 and CCL2) in human lung 
mast cells. These striking differences might be explained by the 
following facts: (i) different activation signals can trigger dis-
tinct mast cell responses (30, 59). In our study, mast cells were 
stimulated with antibiotic-lysed bacteria, whereas live bacteria 
(albeit the same strain) and recombinant PLY were used in the 
other studies, respectively (10, 11). (ii) Mast cells exhibit a high 
degree of phenotypic heterogeneity and plasticity (61). In our 
study, experiments were conducted in mouse bone marrow cells 
differentiated into mast cells by propagation over 4–6 weeks in 
the presence of IL-3 and SCF, whereas rat or human mast cell 
lines as well as primary human mast cells which were purified 
from macroscopically normal lung tissue obtained from cancer 
resections were employed in the other studies. Taken together, 
the existing data indicate that mast cells are capable of reacting 
to S. pneumoniae infection. However, the response pattern likely 
varies between different stimuli and mast cell populations.
Intriguingly, although we found in  vitro and histological 
evidence for mast cell activation upon S. pneumoniae exposure, 
we did not see any effect of mast cell deficiency (by using two 
different Kit mutant mouse strains) on the disease phenotype, 
bacterial outgrowth, and CNS inflammation (except for an 
increase in CSF pleocytosis) in an in vivo meningitis model. One 
potential explanation for this discrepancy may be that although 
brain mast cells may respond to CSF S. pneumoniae infection 
with the release of cytokines, their total output is negligible in 
comparison with contributions from other cells, e.g., resident 
macrophages. In this context it is important to point out that 
mast cells represent only a minor population of cells with the 
leptomeningeal space (the site of infection in meningitis) (7, 8). 
Another possible explanation for the apparent differences 
between the cytokine responses seen in  vitro and in  vivo is 
that the mast cell phenotype and consequently their response 
pattern may differ between the in vitro situation and in vivo (61). 
Culture of bone marrow-derived progenitor mast cells with IL-3 
and SCF facilitates maturation toward a connective-tissue type 
phenotype (62, 63). Although CNS mast cells belong predomi-
nantly to this phenotype, there are also other subpopulations 
including mucosal type and mixed type mast cells present 
in the meninges and brain parenchyma (41, 64), illustrating 
substantial mast cell heterogeneity within the CNS. In addition, 
the mast cell heterogeneity can probably dynamically change in 
accordance with microenvironmental conditions (e.g., altera-
tions in cytokine levels, cell–cell contacts, etc.) that dictate their 
gene expression and phenotypic development (61). Since the 
microenvironmental conditions where mast cell phenotypic 
development occurs in vivo cannot be fully mimicked in vitro, 
cultured mast cells are inevitably incomplete representatives of 
mature tissue mast cells.
Despite similar cytokine production profiles, Kit mutant 
mice exhibited significantly higher leukocyte (particularly 
neutrophil) counts in the CSF 18 h after pneumococcal infec-
tion as compared with mast cell-sufficient control mice. Our 
observation is in conflict with the long time widely accepted 
theory that mast cells contribute to neutrophil recruitment in 
infectious diseases as initially reported by Echtenacher and 
Malaviya and their respective coworkers (15, 16). Accordingly, 
a more recent study in a mouse model of pneumococcal pneu-
monia demonstrated a reduction of leukocyte recruitment into 
lung tissue during established disease in mast cell-deficient 
KitW-sh/W-sh mice (12). Although the exact reasons for this dispa-
rate findings remain elusive, evidence exists that (i) the innate 
immune responses to S. pneumoniae infection differ between 
the lung and CNS (65, 66) and (ii) mast cells can have no effect 
on, promote or block leukocyte infiltration, depending on the 
mouse strain background, the nature of the mutation resulting 
in a mast cell deficiency, and type and severity of infection (25, 
26). Furthermore, it is worth mentioning that i.c. mast cell 
reconstitution only partially reverses CSF leukocyte counts to 
values seen in infected mast cell-sufficient mice. Local mast 
cell reconstitution (in mast cell-deficient Kit mutant mouse 
strains) is considered as the mainstay to study mast cell function 
in  vivo. Although engrafted BMMC can adopt the phenotype 
of normal tissue mast cells after transfer, numbers, distribu-
tion, and functional responses of reconstituted mast cells may 
not be physiological (67, 68). Hence, it seems not possible to 
define the exact contribution of mast cells (or to be precise their 
deficiency) to the increase in CSF pleocytosis observed in our 
study. Nonetheless, we think that its incomplete reversal by 
mast cell engraftment may point at other c-Kit mutation-related 
mechanisms (whose identification was beyond the scope of this 
study) than mast cell deficiency. This hypothesis is supported by 
our observation that i.c. treatment with the mast cell stabilizer 
cromoglyate showed no effect on leukocyte recruitment into the 
CSF in response to S. pneumoniae infection.
Mast cells can also participate in direct killing of pathogens 
by phagocytosis, extracellular trap formation, and/or the release 
of antimicrobial peptides, such as the cathelicidin LL-37 (13, 14). 
Accordingly, human lung mast cells were reported to exhibit 
direct antimicrobial activity to S. pneumoniae upon activation by 
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the bacterial toxin PLY. This antimicrobial activity is mediated, 
at least partly, by the secretion of LL-37 from mast cells (11). 
Paradoxically, in a mouse model of pneumococcal pneumonia, 
mast cell deficiency did not significantly influence the clearance 
of PLY-sufficient S. pneumoniae strain, whereas its isogenic 
PLY-deficient mutant was cleared more rapidly in mast cell-
deficient mice (KitW-sh/W-sh mice), suggesting even an improved 
host defense against pneumococcal infection in mice with pro-
found mast cell deficiency. Contrary to both studies, we did not 
detect any differences in bacterial loads in the brain and blood 
between mast cell-sufficient and mast cell-deficient Kit mouse 
mutant strains as well as vehicle- or cromoglycate-treated mice. 
This observation may be related to the well-known immune 
incompetence inside the CSF-filled leptomeningeal space, such 
as a lack of complement factors, hampering antibacterial effector 
mechanisms (2).
In conclusion, we have shown that (i) mouse BMMC 
degranulate and release selected cytokines upon exposure to 
S. pneumoniae, (ii) the response of BMMC varies between dif-
ferent pneumococcal serotypes and (iii) is dependent on PLY. 
Intriguingly though, we did neither observe any effects of mast 
cell deficiency nor of pharmacologic mast cell stabilization on 
the disease phenotype in a well-established mouse model of 
pneumococcal meningitis. Hence, mast cells are unlikely to act 
as sentinels of pneumococcal CSF invasion and initiators of the 
host immune response inside the CSF.
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FigUre s1 | Effect of mast cell deficiency on cytokine mRNA expression within 
the brain following intracisternal pneumococcal infection. (a) A mouse 
inflammatory cytokines and receptors oligonucleotide array was used to 
determine the differences in the mRNA expression of cytokines, chemokines, 
and other inflammatory factors from PBS-injected WBB6F1-Kit+/+ controls  
(left image) as well as Streptococcus pneumoniae-infected WBB6F1-Kit+/+ mice 
(middle image) and WBB6F1-KitW/Wv mice (right image). The expression of 
multiple cytokines, chemokines, and related inflammatory factors was 
upregulated or induced in brains from infected WBB6F1-Kit+/+ mice. The 
expression level of all these factors did not differ between brains from infected 
WBB6F1-Kit+/+ and WBB6F1-KitW/Wv mice. (B) A scheme of the oligonucleotide 
array membrane: inflammatory factors that were upregulated more than fourfold 
or clearly induced in infected mice are marked with yellow. (c) Using mRNA 
isolated from mouse brains, the relative expressions of IL-1β and IL-33 were 
analyzed in comparison to the housekeeping gene aldolase using quantitative 
RT-PCR. Data are given as mean ± SD. *P < 0.05, compared to infected 
WBB6F1-Kit+/+ mice, #P < 0.05, compared to infected WBB6F1-KitW/Wv mice, 
using ANOVA and Student–Newman–Keuls test for post hoc analysis.
FigUre s2 | Effect of cromoglycate treatment on the BMMC response to 
pneumococcal challenge. In order to evaluate the mast cell-inhibitory potential of 
cromoglycate (cg), we tested the responsiveness of murine BMMC to 
pneumococcal challenge (107 cfu/ml) in the absence or presence of different CG 
concentrations. Supernatants were collected 6 h after challenge, and IL-6 (a), 
CCL2 (B), β-hexosaminadase (c), and LDH (D) concentrations were analyzed by 
standard assays. All experiments were repeated thrice in triplicates. Data are 
given as mean ± SD. *P < 0.05, compared to vehicle (=PBS)-treated, stimulated 
BMMC, #P < 0.05, compared to unstimulated BMMC, using ANOVA and 
Student–Newman–Keuls test for post hoc analysis.
FigUre s3 | Analysis of pneumolysin production by Streptococcus pneumoniae 
serotypes. Pneumolysin production of the each pneumococcal strain was tested 
using a standard hemolysis assay (a) and Western blot analysis (B). The 
presence of pneumolysin is indicated by disintegration of the red blood cell pellet 
within the well in the hemolysis assay and by a single band of approximately 53 
kDa in the Western blot analysis. Antibiotic-lysed S. pneumoniae of the serotypes 
2 (pneumolysin-sufficient or -deficient strain), 3, 7F, and 19A were used as 
samples in both investigations.
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